Καναδάς - Αγγλικά - Health Canada

charlotte products ltd. - silver dihydrogen citrate; citric acid - solution - 0.003%; 4.846% - silver dihydrogen citrate 0.003%; citric acid 4.846% - disinfectants (for agents used on object)

Καναδάς - Αγγλικά - Health Canada

charlotte products ltd. - octyl decyl dimethyl ammonium chloride; dioctyl dimethyl ammonium chloride; didecyl dimethyl ammonium chloride; benzalkonium chloride - solution - 6.51%; 3.255%; 3.255%; 8.68% - octyl decyl dimethyl ammonium chloride 6.51%; dioctyl dimethyl ammonium chloride 3.255%; didecyl dimethyl ammonium chloride 3.255%; benzalkonium chloride 8.68% - disinfectants (for agents used on object)

Καναδάς - Αγγλικά - Health Canada

charlotte products ltd. - hydrogen peroxide; benzalkonium chloride - liquid - 3.95%; 2.50% - hydrogen peroxide 3.95%; benzalkonium chloride 2.50% - disinfectants (for agents used on object)

Καναδάς - Αγγλικά - Health Canada

charlotte products ltd. - hydrogen peroxide - solution - 7.25% - hydrogen peroxide 7.25% - disinfectants (for agents used on object)

Καναδάς - Αγγλικά - Health Canada

charlotte products ltd. - benzalkonium chloride; alkyl dimethyl ethylbenzyl ammonium chloride - solution - 5%; 5% - benzalkonium chloride 5%; alkyl dimethyl ethylbenzyl ammonium chloride 5% - disinfectants (for agents used on object)

Καναδάς - Αγγλικά - Health Canada

charlotte products ltd. - dioctyl dimethyl ammonium chloride; benzalkonium chloride - solution - 5.26%; 3.51% - dioctyl dimethyl ammonium chloride 5.26%; benzalkonium chloride 3.51% - disinfectants (for agents used on object)

Καναδάς - Αγγλικά - Health Canada

charlotte products ltd. - citric acid - solution - 2.5% - citric acid 2.5% - disinfectants (for agents used on object)

Καναδάς - Αγγλικά - Health Canada

charlotte products ltd. - benzalkonium chloride; didecyl dimethyl ammonium chloride - solution - 3.38%; 5.07% - benzalkonium chloride 3.38%; didecyl dimethyl ammonium chloride 5.07% - disinfectants (for agents used on object)

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

solco healthcare us, llc - amphetamine sulfate (unii: 6dpv8nk46s) (amphetamine - unii:ck833kgx7e) - amphetamine sulfate tablets, usp, are indicated for: controlled substance amphetamine sulfate tablets contain amphetamine, a schedule ii controlled substance. abuse amphetamine sulfate tablets have a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction (see warnings ). amphetamine sulfate tablets can be diverted for non-medical use into illicit channels or distribution. abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activit

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

bryant ranch prepack - amphetamine sulfate (unii: 6dpv8nk46s) (amphetamine - unii:ck833kgx7e) - amphetamine sulfate tablets, usp, are indicated for: 1. narcolepsy 2. attention deficit disorder with hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfunction may or not be warranted. 3. exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction for patients refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs. the limited usefulness of amphetamines (see clinical pharmacology) should be weighed against possible risks inherent in use of the drug, such as those described below. advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines. agitated states. patients with a history of drug abuse. during or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result). amphetamine sulfate tablets are a schedule ii controlled substance. amphetamines have been extensively abused. tolerance, extreme psychological dependence, and severe social disability have occurred. there are reports of patients who have increased the dosage to many times the recommended. abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep eeg. manifestations of chronic intoxication with amphetamines include severe dermatosis, marked insomnia, irritability, hyperactivity and personality changes. the most severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia. this is rare with oral amphetamines.